Aadi Biosciences (AADI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AADI Aadi Biosciences

Watchlist

1.960
0.0000.00%

Trading Oct 31 13:20 ET

48.25MMarket Cap-806P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update
PR NewswireOct 30 16:05 ET
Express News | The Arbitration Panel Issued A Final Award Which Found And Concluded That Aadi Bioscience Did Not Breach The EOC Pharma License Agreement And Accordingly Is Not Liable For Any Damages To EOC - Filing
BenzingaSep 30 06:17 ET
Aadi Bioscience Downgraded to Neutral, Shares Fall
Seeking AlphaAug 27 12:20 ET
Piper Sandler Downgrades Aadi Biosciences(AADI.US) to Hold Rating, Cuts Target Price to $1.75
Moomoo NewsAug 27 05:32 ET · Ratings
Express News | Aadi Bioscience Inc : Piper Sandler Cuts to Neutral From Overweight
ReutersAug 27 03:36 ET
Express News | Aadi Bioscience Inc - Desai Will Continue to Serve as a Member of Board
ReutersAug 22 16:18 ET

Comments

Jaguar8

Aug 20 16:01

NEWS

$Aadi Biosciences (AADI.US)$
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
Aadi Bioscience (NASDAQ: AADI) has announced the halt of its PRECISION1 trial for nab-sirolimus in solid tumors with TSC1 or TSC2 alterations due to unlikely regulatory approval. The company will now focus on its FYARRO® commercial business for PEComa and conduct a strategic review. To extend cash runway into at least 2H 2026, Aadi will:
Adjust ongoing Phase 2 trials
Reduce R&D headcount by 80%
Pause...

Jaguar8

May 23 16:34

$Aadi Biosciences (AADI.US)$
NEWS
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
Aadi Bioscience presented new nonclinical data at the ASCO Annual Meeting showing that nab-sirolimus achieved higher intratumoral drug concentrations, stronger mTOR target inhibition, and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model. These findings suppo...

Moomoo AI

Mar 8 06:17

Aadi Bioscience's low P/S ratio may be due to its poor revenue outlook. Investors may believe the potential for revenue improvement doesn't justify a higher P/S ratio. These conditions could continue to limit the share price.